Find a Provider

Steven M. Albelda, MD

Steven M. Albelda, MD Physician

Vice Chief and Director, Lung Research, Pulmonary and Critical Care Medicine
William Maul Measey Professor of Medicine

Dr. Albelda is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Pulmonary Medicine

Programs & Services:

  • Cancer
    • Lung Cancer
    • Mesothelioma
  • Lung
    • Medical Critical Care
    • Mesothelioma & Pleural Disease

Board Certification:

  • Pulmonary Disease, 1984

Conditions & Treatments:

  • Lung Cancer
  • Lung Carcinoid Tumor
  • Mesothelioma
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

Practice Locations and Appointments

  • Harron Lung Center

    Perelman Center for Advanced Medicine West Pavilion, 1st Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Society for Clinical Investigation, National American Society of Gene Therapy, 2004-2008 Committee Member, Cancer Gene Therapy Committee, National American Thoracic Society, National Laenec Society of Pulmonary Physicians, Local Member of Executive Committee, International Mesothelioma Interest Group, International National Cancer Institute: Ad Hoc Study Reviewer: Cancer Therapeutics, National National Cancer Institute: Ad Hoc Study Reviewer: Cancer Therapeutics, National Sigma Xi, Research Society of North America, Associate Member, National


Dr. Albelda is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Research Interests:

Immuno-gene Therapy for Thoracic Malignancies
Lung cancer and other thoracic malignancies are the leading cause of cancer deaths in the United States today. The Thoracic Oncology Research Laboratory is focusing on the design of new treatment strategies for lung cancer and mesothelioma based on the rapidly evolving disciplines of molecular biology, immunotherapy, and gene therapy.
Dr. Albelda’s research is translational in focus and includes animal models, work with human tumor samples, and the conduct of clinical trials. This work is primarily funded through a recently renewed Program Project from the National Cancer Institute and participation in a number of RO1 grants.
The tumor microenvironment is one area of active study. Studies are underway with the goals of 1) a better understanding of the biology of the tumor microenvironment with a focus on the immunuosuppressive activities of white blood cells and fibroblasts, 2) novel approaches to alter the tumor microenvironment to enhance immunotherapy including studying effects using COX-2 inhibitors, TGFbeta inhibitors, T-regulatory cell inhibitors., antibodies against B-cells, and chemotherapeutic drugs. A second area of interest in the lab is the use of adoptive T cell transfer to treat lung malignancies. Studies are underway to modify T cells in order to make them traffic more efficiently into tumors, to have better killing function, and to resist inactivation by the tumor microenvironment. A T cells targeting cancer-associated fibroblasts is being developed. In addition, Dr. Albelda is closely involved with a number of immunogene clinical trials at Penn using an adenovirus expressing the immune-activator interferon-alpha that is instilled into the pleural space of mesothelioma patients (in collaboration with Dr. Daniel Sterman) and T cells altered to attack the mesothelioma tumor target, mesothelin (in collaboration with Drs. Carl June and Andrew Haas).

Selected Publications:

Kennedy Gregory T, Okusanya Olugbenga T, Keating Jane J, Heitjan Daniel F, Deshpande Charuhas, Litzky Leslie A, Albelda Steven M, Drebin Jeffrey A, Nie Shuming, Low Philip S, Singhal Sunil: The Optical Biopsy: A Novel Technique for Rapid Intraoperative Diagnosis of Primary Pulmonary Adenocarcinomas. Annals of surgery 262 (4): 602-9,2015.

Moon Edmund K, Ranganathan Raghuveer, Eruslanov Evgeniy, Kim Soyeon, Newick Kheng, O'Brien Shaun, Lo Albert, Liu Xiaojun, Zhao Yangbing, Albelda Steven M: Blockade of Programmed Death 1 Augments the Ability of Human T cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clinical cancer research : an official journal of the American Association for Cancer Research : 2015.

Fridlender Zvi G, Albelda Steven M, Granot Zvi: Promoting metastasis: neutrophils and T cells join forces. Cell research 25 (7): 765-6,2015.

Lo Albert, Wang Liang-Chuan S, Scholler John, Monslow James, Avery Diana, Newick Kheng, O'Brien Shaun, Evans Rebecca A, Bajor David J, Clendenin Cynthia, Durham Amy C, Buza Elizabeth L, Vonderheide Robert H, June Carl H, Albelda Steven M, Puré Ellen: Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer research 75 (14): 2800-10,2015.

Kennedy Gregory T, Judy Brendan F, Bhojnagarwala Pratik, Moon Edmund K, Fridlender Zvi G, Albelda Steven M, Singhal Sunil: Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma. Immunology letters 166 (1): 28-35,2015.

Mesaros Clementina, Worth Andrew J, Snyder Nathaniel W, Christofidou-Solomidou Melpo, Vachani Anil, Albelda Steven M, Blair Ian A: Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis 7 (9): 1157-73,2015.

Enxiu Wang, E., Wang, L.C., Tsai, C.Y., Bhoj, V., Moon, E., Newick, K., Sun, J., Lo A., Puré, E., Baradet, T., Feldman, M., Albelda, S.M., Milone, M.C.: Killer Immunoglobulin-like Receptor (KIR)-based Chimeric Antigen Receptors (CARs) for Adoptive T cell Immunotherapy. Cancer Immunology Research 7 : 815-26,2015.

Eruslanov Evgeniy B, Bhojnagarwala Pratik S, Quatromoni Jon G, Stephen Tom Li, Ranganathan Anjana, Deshpande Charuhas, Akimova Tatiana, Vachani Anil, Litzky Leslie, Hancock Wayne W, Conejo-Garcia José R, Feldman Michael, Albelda Steven M, Singhal Sunil: Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. The Journal of clinical investigation 124 (12): 5466-80,2014.

Okusanya Olugbenga T, Holt David, Heitjan Daniel, Deshpande Charuhas, Venegas Ollin, Jiang Jack, Judy Ryan, DeJesus Elizabeth, Madajewski Brian, Oh Kenny, Wang May, Albelda Steven M, Nie Shuming, Singhal Sunil: Intraoperative near-infrared imaging can identify pulmonary nodules. The Annals of thoracic surgery 98 (4): 1223-30,2014.

Moon Edmund K, Wang Liang-Chuan, Dolfi Douglas V, Wilson Caleph B, Ranganathan Raghuveer, Sun Jing, Kapoor Veena, Scholler John, Puré Ellen, Milone Michael C, June Carl H, Riley James L, Wherry E John, Albelda Steven M: Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 20 (16): 4262-73,2014.

View all publications

Academic Contact Info

1016B Abramson Research Center
3615 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 573-9933
Fax: (215) 573-4469
Patient appointments: 800-789-PENN (7366)

Related Links